{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:51:28Z","timestamp":1792014688685,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtocrr.2026.101009","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:58:08Z","timestamp":1777733888000},"page":"101009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perioperative Pembrolizumab in Japanese Participants With Early-Stage NSCLC: Subgroup Analysis From KEYNOTE-671"],"prefix":"10.1016","volume":"7","author":[{"given":"Masahiro","family":"Tsuboi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihito","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Takamochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sugio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Horio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101009_bib1","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101009_bib2","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2026.101009_bib3","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101009_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101009_bib5","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101009_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jtocrr.2026.101009_bib7","series-title":"Full Prescribing Information","year":"2025"},{"key":"10.1016\/j.jtocrr.2026.101009_bib8","series-title":"Full Prescribing Information","year":"2025"},{"key":"10.1016\/j.jtocrr.2026.101009_bib9","series-title":"Full Prescribing Information","year":"2024"},{"key":"10.1016\/j.jtocrr.2026.101009_bib10","series-title":"Full Prescribing Information","year":"2024"},{"key":"10.1016\/j.jtocrr.2026.101009_bib11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2026.101009_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.athoracsur.2025.10.016","article-title":"Clinical characteristics and surgical outcomes of patients receiving perioperative pembrolizumab in KEYNOTE-671","volume":"121","author":"Liberman","year":"2026","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtocrr.2026.101009_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1092355","article-title":"Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: a Texas study","volume":"12","author":"Olateju","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2026.101009_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7080","article-title":"East Asian patients who received immunotherapy-based therapy associated with improved survival benefit in advanced non-small cell lung cancer: an updated meta-analysis","volume":"13","author":"Yao","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtocrr.2026.101009_bib15","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1002\/ijc.32717","article-title":"Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: an ancillary analysis of the Poplar and OAK studies","volume":"146","author":"Qian","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtocrr.2026.101009_bib16","doi-asserted-by":"crossref","first-page":"S1482","DOI":"10.21037\/jtd.2018.05.106","article-title":"Immunotherapy in the Asiatic population: any differences from Caucasian population?","volume":"10","author":"Peng","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtocrr.2026.101009_bib17","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1111\/cas.15564","article-title":"Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010)","volume":"113","author":"Kenmotsu","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtocrr.2026.101009_bib18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cas.16030","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816","volume":"115","author":"Mitsudomi","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtocrr.2026.101009_bib19","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1111\/cas.15816","article-title":"Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407","volume":"114","author":"Sugawara","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtocrr.2026.101009_bib20","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1111\/cas.14980","article-title":"Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan study","volume":"112","author":"Horinouchi","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtocrr.2026.101009_bib21","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/cas.14817","article-title":"IMpower132: atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients","volume":"112","author":"Nishio","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtocrr.2026.101009_bib22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s10147-024-02620-1","article-title":"PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of alectinib and pembrolizumab for the adjuvant treatment of non-small cell lung cancer in Japan","volume":"29","author":"Matsumura","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101009_bib24","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:20:46Z","timestamp":1792012846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326000603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666364326000603"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101009","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative Pembrolizumab in Japanese Participants With Early-Stage NSCLC: Subgroup Analysis From KEYNOTE-671","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s), Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101009"}}